BIO-RAD Laboratories (NYSE: BIO) financial statements
The consolidated income statement, balance sheet and cash flow statement of BIO-RAD Laboratories for its last 10 fiscal years, as filed with the regulator, in millions of US dollars. At the end of fiscal 2025 it had $10,577m in total assets and $7,454m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2,583m | $2,567m | $2,671m | $2,802m | $2,923m | $2,546m | $2,312m | $2,289m | $2,160m | $2,068m |
| Cost of sales | $1,243m | $1,188m | $1,244m | $1,235m | $1,284m | $1,108m | $1,055m | $1,066m | $972.5m | $929.7m |
| Gross profit | $1,340m | $1,379m | $1,427m | $1,567m | $1,638m | $1,438m | $1,257m | $1,223m | $1,188m | $1,138m |
| Operating profit | $47.2m | $269.0m | $337.8m | $482.6m | $500.3m | $421.3m | $229.7m | −$103.3m | $119.3m | $55.7m |
| Finance costs | $49.0m | $48.9m | $49.4m | $38.1m | $1.6m | $21.9m | $23.4m | $24.0m | $21.9m | $21.9m |
| Profit before tax | $995.5m | −$2,343m | −$850.1m | −$4,704m | $5,449m | $4,918m | $2,261m | $512.7m | $97.8m | $41.6m |
| Income tax | $235.6m | $498.3m | $212.8m | $1,077m | $1,195m | $1,104m | $502.4m | $147.0m | $24.4m | $15.6m |
| Net profit | $759.9m | −$1,844m | −$637.3m | −$3,628m | $4,254m | $3,814m | $1,759m | $365.6m | $122.2m | $26.0m |
| Earnings per share | $27.87 | −$65.36 | −$21.82 | −$121.79 | $142.33 | $127.86 | $58.93 | $12.25 | $4.12 | $0.88 |
| Diluted earnings per share | $27.85 | −$65.36 | −$21.82 | −$121.79 | $140.56 | $126.20 | $58.27 | $12.10 | $4.07 | $0.88 |
| Depreciation and amortisation | $165.4m | $151.6m | $145.9m | $137.3m | $137.6m | $138.6m | $134.2m | $138.1m | $148.7m | $142.9m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10,577m | $9,364m | $12,299m | $13,502m | $17,799m | $12,973m | $8,009m | $5,611m | $4,273m | $3,851m |
| Current assets | $2,906m | $3,030m | $3,048m | $3,158m | $1,990m | $2,140m | $2,180m | $2,023m | $1,977m | $1,845m |
| Inventories | $740.7m | $760.0m | $780.5m | $719.3m | $572.2m | $622.3m | $554.0m | $583.8m | $594.8m | $525.0m |
| Property, plant and equipment | $539.9m | $528.1m | $529.0m | $498.6m | $511.6m | $491.4m | $499.3m | $508.7m | $493.5m | $488.6m |
| Goodwill | $579.8m | $410.5m | $413.6m | $406.5m | $347.3m | $291.9m | $264.1m | $219.8m | $506.1m | $477.1m |
| Cash | $529.8m | $488.1m | $403.8m | $434.2m | $470.8m | $662.2m | $660.7m | $431.5m | $383.8m | $456.3m |
| Total liabilities | $3,123m | $2,795m | $3,558m | $3,886m | $4,114m | $3,093m | $2,254m | $1,591m | $1,343m | $1,271m |
| Current liabilities | $517.0m | $467.8m | $522.8m | $568.7m | $680.9m | $631.5m | $905.5m | $450.8m | $502.7m | $471.3m |
| Equity | $7,454m | $6,569m | $8,741m | $9,615m | $13,685m | $9,890m | $5,757m | $4,020m | $2,930m | $2,579m |
| Equity including minorities | $7,454m | $6,569m | $8,741m | $9,615m | $13,685m | $9,890m | $5,757m | $4,020m | $2,930m | $2,579m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $532.2m | $455.2m | $374.9m | $194.4m | $669.5m | $585.0m | $457.9m | $285.5m | $104.1m | $216.1m |
| Investing cash flow | −$189.7m | −$160.2m | $20.2m | −$1,208m | −$797.4m | −$69.9m | −$208.9m | −$187.0m | −$175.6m | −$213.9m |
| Financing cash flow | −$283.2m | −$218.8m | −$425.6m | $973.6m | −$55.4m | −$523.0m | −$22.8m | −$48.7m | $0.3m | $9.0m |
| Capital expenditure | −$157.6m | −$165.6m | −$156.7m | −$112.8m | −$133.7m | −$108.6m | −$98.5m | −$129.8m | −$111.3m | −$141.4m |
Where each figure comes from
From the annual report (Form 10-K) that BIO-RAD Laboratories files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the BIO-RAD Laboratories page.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.